Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 11177-HV

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
11177-HV-100
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

HEK293

Accession #

Q92956.3

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

View all HVEM/TNFRSF14 Proteins and Enzymes »

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived human HVEM/TNFRSF14 protein
Human HVEM/TNFRSF14
(Pro37-Val202)
Accession # Q92956.3		 IEGRMD Human IgG1
(Pro100-Lys330)
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Pro37

Predicted Molecular Mass

44 kDa

SDS-PAGE

55-75 kDa, under reducing conditions.

Activity

Measured by its binding ability in a functional ELISA.
When Recombinant Human BTLA (Catalog # 9235-BT) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human HVEM/TNFRSF14 Fc Chimera (Catalog # 11177-HV) binds with an ED50 of 50.0-600 ng/mL.

Scientific Data Images for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein Binding Activity.

When Recombinant Human BTLA (9235-BT) is immobilized at 1 µg/mL (100 µL/well), Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein (Catalog # 11177-HV) binds with an ED50 of 50.0-600 ng/mL.

Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein SDS-PAGE.

2 μg/lane of Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein (Catalog # 11177-HV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 55-75 kDa and 110-150 kDa, respectively.

Formulation, Preparation and Storage

11177-HV
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: HVEM/TNFRSF14

Herpesvirus entry mediator (HVEM), also known as TNFRSF14 and CD270, is a type I membrane protein in the TNF receptor superfamily. Originally identified as important for entry of herpes simplex virus (HSV) through recognition of HSV glycoprotein D (gD), HVEM has been shown to be involved in the regulation of T cell activity (1). Mature human HVEM consists of an extracellular domain (ECD) with four cysteine-rich domains (CRD), a transmembrane segment, and a cytoplasmic region with a TRAF interaction domain (2). The ECD of human HVEM shares 51% amino acid sequence identity with mouse HVEM. HVEM is found on the membrane of various cell types, including hematopoietic and non-hematopoietic cells, with higher expression in the lung, kidney, and liver (3). HVEM is a receptor for the TNF ligand LIGHT, Ig superfamily members BTLA and CD160, as well as Lymphotoxin-alpha and is involved in bidirectional signaling as both a signaling receptor and a ligand for inhibitory receptors (1,4). Ligation of HVEM by LIGHT triggers T cell, monocyte, and neutrophil activation (5,6). In contrast, HVEM binding to CD160 or BTLA suppresses T cell and dendritic cell activation (3,6,7). HVEM enhances the development of CD8+ T cell memory and Treg function (8, 9). It is additionally expressed on intestinal epithelial cells, where its binding by intraepithelial lymphocyte (IEL) expressed CD160 promotes epithelial integrity and host defense (10). HVEM is being investigated as an immune checkpoint inhibitor as it is commonly mutated in lymphomas, while upregulation leads to disease progression and is associated with poor prognosis (11, 12).

References

  1. Steinberg, M.W. et al. (2011) Immunological reviews 244:169.
  2. Liu, W. et al. (2021) J Exp Med. 218:e20211112).
  3. Demerlé C. et al. (2021) Front Oncol. 2021 11:682007.
  4. del Rio, M.L. et al. (2010) J. Leukoc. Biol. 87:223.
  5. Heo, S.K. et al. (2006) J. Leukoc. Biol. 79:330.
  6. Cai, G. et al. (2008) Nat. Immunol. 9:176.
  7. Gonzalez, L.C. et al. (2005) Proc. Natl. Acad Sci. USA 102:1116.
  8. Tao, R. et al. (2008) J. Immunol. 180:6649.
  9. Steinberg, M.W. et al. (2013) PLoS One 8:e77992.
  10. Shui, J.W. et al. (2012) Nature 488:222.
  11. Aubert, N. et al. (2021) Cancers (Basel) 13:3009.
  12. Boice, M. et al. (2016) Cell. 167:405.

Long Name

Herpesvirus Entry Mediator

Alternate Names

ATAR, CD270, LIGHTR, TNFRSF14

Entrez Gene IDs

8764 (Human); 230979 (Mouse); 102137807 (Cynomolgus Monkey)

Gene Symbol

TNFRSF14

UniProt

Q92956.3

Additional HVEM/TNFRSF14 Products

Product Documents for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Human HVEM/TNFRSF14 Fc Chimera Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.